Cite
HARVARD Citation
Brown, L. et al. (2021). LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. Journal for immunotherapy of cancer. 9 (3), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Brown, L. et al. (2021). LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. Journal for immunotherapy of cancer. 9 (3), p. . [Online].